Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director · Former EVP, CFO, & Director | November 15, 2023 | November 17, 2023 |
| Altimmune, Inc.ALT · Entity 5349 | Chief Financial Officer | October 01, 2026 | October 05, 2026 |
| Atai Beckley N.V.ATAI · Entity 72536 | Chief Financial Officer | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date November 15, 2023 · Filed November 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55 |
Reported balance
After 2023-11-15 transaction · row 1
1 source rowRow 1 · 2023-11-15 · Sale · Disposed 50,000 · Balance 55 |
Altimmune, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 49,927 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 14,475 · Balance 54,306 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-10-01 · Tax withholding · Disposed 4,379 · Balance 49,927 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 43,425 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 14,475 · Balance 43,425 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Atai Beckley N.V.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2032-03-01 | Direct | 228,000 |
Reported balance
After 2022-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-02 · Grant · Acquired 228,000 · Balance 228,000 F1: The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date March 15, 2020 · Filed March 16, 2020
Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,431 |
Ending reported balance
After 2020-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-15 · Exercise / conversion · Acquired 3,750 · Balance 11,517 F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. Row 2 · 2020-03-15 · Tax withholding · Disposed 1,086 · Balance 10,431 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-15 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited.
Zyla Life Sciences
Report date January 31, 2019 · Filed February 05, 2019
Section 16 reporting ended · disclosed 2019-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2024-02-04 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Disposition to issuer · Disposed 2,083 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2024-06-09 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-31 · Disposition to issuer · Disposed 667 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2024-09-30 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-31 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-31 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-31 · Disposition to issuer · Disposed 29,666 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-31 · Disposition to issuer · Disposed 58,133 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001251779-26-000011 · form4-10052026_041006.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,425 Underlying: Common Stock, par value $0.0001 · 14,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,379 | $2.76 | $12,086.04 |
DisclosureSEC source: 0001251779-26-000011 · form4-10052026_041006.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,927 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001251779-26-000011 · form4-10052026_041006.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,753 | $2.41 | $4,231.74 |
DisclosureSEC source: 0001251779-26-000009 · form4-08032026_040813.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,831 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 10,000 | $3.15 | $31,499.00 |
DisclosureSEC source: 0001251779-26-000007 · form4-04012026_040406.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,078 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.1450 to $3.1499, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 11:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,000 | $3.54 | $17,700.00 |
DisclosureSEC source: 0001251779-26-000005 · form4-03092026_070301.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,078 Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 111,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001251779-26-000002 · form4-02272026_040231.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock, par value $0.0001 · 111,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 259,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001251779-26-000002 · form4-02272026_040231.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,000 Underlying: Common Stock, par value $0.0001 · 259,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:07 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001251779-25-000006 · form4-11122025_091117.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock, par value $0.0001 · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:07 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 5,672 | $4.28 | $24,276.16 |
DisclosureSEC source: 0001251779-25-000006 · form4-11122025_091117.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,078 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:07 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001251779-25-000006 · form4-11122025_091117.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:24 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 57,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-096679 · tm2527887-3_4seq1.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,900 Underlying: Common Stock, par value $0.0001 · 57,900 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:24 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 166,800 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-25-096679 · tm2527887-3_4seq1.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,800 Underlying: Common Stock, par value $0.0001 · 166,800 shares Expires 2035-10-01 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 11:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 10,000 | $5.20 | $51,996.00 |
DisclosureSEC source: 0001104659-25-023724 · tm259169-1_4seq1.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.1950 to $5.1997, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:50 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-116882 · tm2428121-2_4seq1.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:50 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 225,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001104659-24-116882 · tm2428121-2_4seq1.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock, par value $0.0001 · 225,000 shares Expires 2034-11-11 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:01 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | SaleCommon Stock | 50,000 | $0.65 | $32,500.00 |
DisclosureSEC source: 0001437749-23-032461 · rdgdoc.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director · Former EVP, CFO, & Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55 Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 00:15 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 50,000 | $0.97 | $48,500.00 |
DisclosureSEC source: 0001437749-23-017896 · rdgdoc.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,055 F1 · price: The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99. Upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes shares of common stock purchased on November 21, 2013, which were previously reported on a Form 4 filed by the Reporting Person on November 22, 2013 but erroneously omitted in subsequent filings. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 13:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 2,600,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001437749-23-016569 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600,000 Underlying: Common Stock · 2,600,000 shares Expires 2033-06-01 F1 · derivative.exercise_date: The options shall vest with respect to 25% on the one year anniversary of June 1, 2023, and the remainder shall vest in equal quarterly installments over the following three years, subject to the reporting person's continued service through each applicable vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 23:36 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001437749-23-012872 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023. Read SEC document |
| May 13, 2022 Filed May 16, 2022 22:19 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001437749-22-012709 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 20:56 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 228,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0000899243-22-009376 · doc4.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Shares · 228,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · derivative · entry 10 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date. F6 · derivative.expiration_date: These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · derivative · entry 9 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date. F5 · derivative.expiration_date: These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · derivative · entry 8 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date. F4 · derivative.expiration_date: These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionStock Option (right to buy) · Derivative | 4,581 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · derivative · entry 7 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date. F3 · derivative.expiration_date: These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | SaleCommon Stock | 107,497 | $5.58 | $599,833.26 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 6 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Tax withholdingCommon Stock | 57,084 | $6.40 | $365,337.60 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 5 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,497 F1 · price: Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionCommon Stock | 70,000 | $1.70 | $119,000.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 4 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionCommon Stock | 45,000 | $2.52 | $113,400.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionCommon Stock | 45,000 | $2.38 | $107,100.00 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Exercise / conversionCommon Stock | 4,581 | $5.64 | $25,836.84 |
DisclosureSEC source: 0001437749-21-016573 · rdgdoc.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:15 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 4,666 | $15.00 | $69,990.00 |
DisclosureSEC source: 0000899243-21-025732 · doc4.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 20:20 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 67,726 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025282 · doc4.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,726 Underlying: Common Shares · 67,726 shares Expires 2031-06-17 F1 · derivative.exercise_date: The stock option vests as to 25% of the underlying shares on June 17, 2022, and the remaining vests in 36 equal monthly installments thereafter. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:16 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012671 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 15, 2020 Filed May 19, 2020 18:06 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-20-011264 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 15, 2020 with an exercise price of $1.70, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| March 15, 2020 Filed Mar 16, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000755 · form4-03162020_040301.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · FORMER CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F4 · balance_after: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. Read SEC document |
| March 15, 2020 Filed Mar 16, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 1,086 | $2.85 | $3,095.10 |
DisclosureSEC source: 0001415889-20-000755 · form4-03162020_040301.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · FORMER CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,431 Read SEC document |
| March 15, 2020 Filed Mar 16, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000755 · form4-03162020_040301.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · FORMER CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:26 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000201 · form4-01312020_020141.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:26 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 1,733 | $3.91 | $6,776.03 |
DisclosureSEC source: 0001415889-20-000201 · form4-01312020_020141.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,767 Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:26 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000201 · form4-01312020_020141.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000636 · form4a-03042020_020302.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: The original Form 4 filed on January 31, 2020 is amended by this Form 4 Amendment to correctly identify the nature of the transaction of the reporting person. F4 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F1 · derivative.expiration_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F5 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 1,733 | $3.91 | $6,776.03 |
DisclosureSEC source: 0001415889-20-000636 · form4a-03042020_020302.xml · nonDerivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,767 Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000636 · form4a-03042020_020302.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. Read SEC document |
| May 17, 2019 Filed May 22, 2019 00:07 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-19-010648 · rdgdoc.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 7 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-05-14 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 58,133 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 6 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,133 shares Expires 2027-06-08 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 29,666 | Not disclosed Strike: $4.98 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 5 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,666 shares Expires 2026-06-15 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $12.08 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 4 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-10 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.